Beacon Rise enters agreement for £0.71 million chiropractor acquisition

Beacon Rise Holdings Plc (LSE:BRS) has entered non-binding terms to acquire Dr Kerry Sissins Chiropractor Limited for approximately £0.71 million in cash, funded by equity and debt. The target practice reported £0.56 million in revenue and £0.17 million in EBITDA for FY2025. This proposed acquisition, alongside other potential deals, highlights Beacon Rise's inorganic growth strategy, but its shares remain suspended on the LSE under 'initial transactions' rules, signifying continued illiquidity for investors until final agreements are reached or transactions are terminated.

Analysis

Gold rallies above key $3,900/oz mark amid yen slump, U.S. rate cut bets LONDON - Beacon Rise Holdings Plc (LSE:BRS) has entered into non-binding heads of terms to acquire Dr Kerry Sissins Chiropractor Limited for approximately £0.71 million, the company announced Monday. The acquisition target, a UK-based private chiropractor practice, would be purchased entirely in cash, according to the company’s statement. Beacon Rise plans to fund the transaction through a combination of equity and debt financing. The proposed deal follows Beacon Rise’s September 29 announcement that it was in preliminary discussions regarding potential acquisitions. The transaction remains subject to due diligence, regulatory and shareholder approvals, and the negotiation of a final binding acquisition agreement. According to unaudited accounts for the year ended April 30, 2025, the chiropractic practice generated revenues of approximately £0.56 million and earnings before interest, taxes, depreciation, and amortization (EBITDA) of approximately £0.17 million. The practice operates with a team that includes a practice manager with over 35 years of experience, three associate chiropractors, and five receptionists. Beacon Rise also reported it continues discussions regarding a proposed acquisition of a training provider, though those talks remain at an early stage with no agreed terms. The company noted that each of its proposed acquisitions are separate and not inter-conditional, meaning they will not be impacted if one fails to complete. If any acquisition does not proceed, Beacon Rise intends to identify replacement targets. Trading in Beacon Rise shares remains suspended on the London Stock Exchange as the proposed acquisitions are classified as "initial transactions" under UK Listing Rules. The suspension will continue until final terms are agreed or the acquisitions are terminated. This information is based on a press release statement from Beacon Rise Holdings. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you be buying BRS right now? ProPicks AI evaluates BRS alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if BRS is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space? Beacon Rise Holdings Plc (LSE:BRS) is executing a stated inorganic growth strategy through a proposed cash acquisition of Dr Kerry Sissins Chiropractor Limited for £0.71 million. Based on the target's unaudited fiscal 2025 figures of £0.56 million in revenue and £0.17 million in EBITDA, the transaction implies a valuation multiple of approximately 4.2x EBITDA, which may be considered reasonable depending on industry benchmarks and growth prospects. The deal, which remains non-binding and subject to due diligence and financing, signals a clear strategic pivot for Beacon Rise into an acquisition-led model, further evidenced by concurrent discussions for another unrelated acquisition. A critical consideration for investors is the continued suspension of BRS shares on the London Stock Exchange, a direct result of the deal's classification as an "initial transaction" under UK Listing Rules. This suspension creates a significant liquidity trap for existing shareholders, as the stock will remain untradeable until the acquisition's terms are finalized or the process is terminated.

Key Decisions for Investors

• Current holders of Beacon Rise shares are locked in an illiquid position due to the trading suspension, which will persist until the proposed acquisitions are either completed or abandoned, making it impossible to adjust positions.
• Investors should scrutinize the final terms of the acquisition and the associated debt and equity financing, as the current approximate 4.2x EBITDA multiple is contingent on successful deal execution and the structure of the financing will determine future dilution and leverage risk.
• The company's value proposition has fundamentally shifted to that of an acquisition vehicle; therefore, future performance will depend primarily on management's ability to identify, finance, and integrate targets effectively, rather than on its previous operational history.
• Monitor for regulatory announcements regarding the lifting of the trading suspension and the finalization of the binding acquisition agreement, as these are the next material catalysts for the stock.